Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Yamato Nagata, Shotaro Akiba, Hidekazu Horiuchi, Kazuo Okumoto, Shigemi Hachinohe, Rintaro Ohe
A 66-year-old woman with rheumatoid arthritis (RA) who had been receiving methotrexate (MTX) for 2 years presented with tarry stools. Contrast-enhanced computed tomography (CT) of the abdomen revealed irregular wall thickening in the ileocecal region and multiple low-contrast masses in both lobes of the liver. Lower gastrointestinal endoscopy revealed a type 2 tumor in the ileocecal region with a semi-peripheral ulcer. Histological examination of liver and colon biopsies showed other iatrogenic immunodeficiency-associated lymphoproliferative disorder (Oi-LPD), diffuse large B-cell lymphoma type, with positivity for Epstein-Barr virus DNA...
April 20, 2024: Clinical Journal of Gastroenterology
#2
Tatsuya Sakaguchi, Shunichi Yoshida, Takeshi Karube, Taneaki Nakagawa, Seiji Asoda
Epstein-Barr virus-positive mucocutaneous ulcer (EBV-MCU) is characterized by ulcers confined to the skin and mucus membranes. EBV-MCU is an EBV-positive lymphoproliferative disorder that occurs during the use of immunosuppressive drugs such as methotrexate. We herein report a case of EBV-MCU in the maxillary gingiva. A 73-year-old woman was referred to our department in March 2021. During the initial examination, bone exposure and ulceration were observed in the extraction socket of the maxillary bilateral central incisors...
March 2024: Curēus
#3
JOURNAL ARTICLE
Kumiko Ohsawa, Shuji Momose, Asami Nishikori, Midori Filiz Nishimura, Yuka Gion, Keisuke Sawada, Morihiro Higashi, Michihide Tokuhira, Jun-Ichi Tamaru, Yasuharu Sato
A subset of patients with rheumatoid arthritis receiving methotrexate develop immune deficiencies and dysregulation-associated lymphoproliferative disorders. Patients with these disorders often exhibit spontaneous regression after MTX withdrawal; however, chemotherapeutic intervention is frequently required in patients with classic Hodgkin lymphoma arising in immune deficiency/dysregulation. In this study, we examined PD-L1 expression levels and 9p24.1 copy number alterations in 27 patients with classic Hodgkin lymphoma arising from immune deficiency/dysregulation...
March 27, 2024: Cancers
#4
Hideaki Tsujii, Ryuko Nakayama, Sohei Funakoshi, Shuhei Tsuji, Hironori Haga, Kazuo Ono
We herein report a case of methotrexate-associated lymphoproliferative disorder (MTX-LPD) showing fibrin-associated large B-cell lymphoma-like heart valve lesions, and Epstein-Barr virus (EBV)-positive mucocutaneous ulcer-like cutaneous and oral mucosal lesions. MTX-LPD is a critical complication that can occur in RA patients who are treated with MTX. EBV also plays a defining or important role in LPDs. Among the sites of MTX-LPD, 40-50% occur in extranodal sites, including the gastrointestinal tract, skin, liver, lung, and kidney...
April 2, 2024: Pathology International
#5
JOURNAL ARTICLE
Mieko Doi, Mei Hamada, Keisuke Ishizawa, Naoki Fushimi, Yasuhiro Kase, Tetsuo Ikezono, Jun-Ichi Tamaru, Taketo Yamada
Epstein-Barr virus-positive mucocutaneous ulcer (EBVMCU) is a newly established immunodeficiency-related disease. Herein, we report a case of EBVMCU and focus on its cytological usefulness for diagnosis. An 82-year-old man manifested pharyngalgia, dysphagia, and oral pain. His medical history included rheumatoid arthritis that had been treated with methotrexate. Clinically, peritonsillar abscess was suspected, but since neoplastic lesions, including malignant lymphoma (ML), could not be excluded, a series of cytohistological examination was attempted...
March 27, 2024: Diagnostic Cytopathology
#6
Koh Kitagawa, Masafumi Oyama, Shohei Asada, Shinya Sato, Tatsuya Nakatani, Naoki Nishimura, Yuka Mui, Jun-Ichi Hanatani, Maiko Takeda, Hitoshi Yoshiji
A 73-year-old woman with a history of rheumatoid arthritis treated with methotrexate (MTX) for the last 10 years was referred to our hospital for a pancreatic tumor examination. Contrast-enhanced abdominal computed tomography revealed a 20-mm-diameter hypovascular tumor in the pancreatic tail. A hypoechoic mass with heterogeneous internal echo was found on an endoscopic ultrasound (EUS). An EUS-guided fine-needle biopsy (EUS-FNB) was performed with a 22-gauge Franseen-tip needle. Histologic examination of EUS-FNB specimens from the pancreatic tumor revealed the proliferation of atypical spindle cells...
April 2024: DEN Open
#7
The first case of methotrexate-associated lymphoproliferative disorder in the sacrum: a case report.
Yuichi Yamaguchi, Tadatsugu Morimoto, Yu Toda, Masatsugu Tsukamoto, Tomohito Yoshihara, Hirohito Hirata, Takaomi Kobayashi, Masaaki Mawatari
Methotrexate (MTX) is a drug used for treating rheumatoid arthritis. Recently, the reported incidence of methotrexate-associated lymphoproliferative disease (MTX-LPD) has increased, especially in Japan. Extranodal involvement is observed in half of MTX-LPD cases. However, only a few spinal lesions have been reported, with none in the sacrum. Additionally, Epstein-Barr virus (EBV) infection has also been implicated in the pathogenesis of MTX-LPD. Herein, we describe the case of a 74-year-old woman with MTX-LPD in the sacral spine who complained of severe back pain and nocturnal pain...
January 2024: BJR Case Reports
#8
JOURNAL ARTICLE
Kazuo Fukumoto, Ryu Watanabe, Minako Tsutsumi, Teruhito Takakuwa, Masafumi Miyamoto, Noriyuki Hayashi, Shinsuke Yamada, Yutaka Furumitsu, Masayuki Hino, Motomu Hashimoto
Lymphoproliferative disorders (LPDs) are serious complications that arise in patients with rheumatoid arthritis (RA) receiving immunosuppressive drugs (ISDs). Here, we report a 73-year-old woman was diagnosed with RA at 60 years of age and treated with methotrexate, bucillamine, prednisolone, and infliximab. She was referred to our hospital with general malaise, pancytopenia, a right adrenal mass, and enlarged periaortic lymph nodes. Epstein-Barr virus (EBV) was detected in serum. We suspected LPD development and performed a bone marrow biopsy, on which no malignant cells could be detected...
February 7, 2024: Modern rheumatology case reports
#9
JOURNAL ARTICLE
Yoshihiko Hoshida, Atsuko Tsujii, Shiro Ohshima, Yukihiko Saeki, Masato Yagita, Tomoya Miyamura, Masao Katayama, Tomonori Kawasaki, Yasushi Hiramatsu, Hisaji Oshima, Toshihiko Murayama, Shinji Higa, Kazuya Kuraoka, Fuminori Hirano, Kenji Ichikawa, Mitsutoshi Kurosawa, Hiroaki Suzuki, Noriyuki Chiba, Takao Sugiyama, Yuko Minami, Hitoshi Niino, Atsushi Ihata, Ikuo Saito, Akiko Mitsuo, Toshitaka Maejima, Atsuhiro Kawashima, Hiroshi Tsutani, Koichiro Takahi, Takahiko Kasai, Yoko Shinno, Yoshiro Tachiyama, Norihiro Teramoto, Kenichi Taguchi, Shinji Naito, Shigeru Yoshizawa, Masahiro Ito, Yasuo Suenaga, Shunsuke Mori, Shoichi Nagakura, Norie Yoshikawa, Mitsuharu Nomoto, Atsuhisa Ueda, Shouhei Nagaoka, Yukio Tsuura, Keigo Setoguchi, Shoji Sugii, Asami Abe, Toshiaki Sugaya, Hiroyuki Sugahara, Shigeki Fujita, Yasuo Kunugiza, Norishige Iizuka, Ryosuke Yoshihara, Hiroki Yabe, Tomoaki Fujisaki, Eiichi Morii, Morishige Takeshita, Masakazu Sato, Kazuyoshi Saito, Kiyoshi Matsui, Yasuhiko Tomita, Hiroshi Furukawa, Shigeto Tohma
OBJECTIVE: In this study, we examine how advancements in novel antirheumatic drugs affect the clinicopathologic features of lymphoproliferative disorder (LPD) in patients with rheumatoid arthritis (RA). METHODS: In this multicenter study across 53 hospitals in Japan, we characterized patients with RA who developed LPDs and visited the hospitals between January 1999 and March 2021. The statistical tools used included Fisher's exact test, the Mann-Whitney U-test, the log-rank test, logistic regression analysis, and Cox proportional hazards models...
January 25, 2024: Arthritis & Rheumatology
#10
JOURNAL ARTICLE
Yoshi Miyamoto, Chihiro Kawasoe, Kaoru Ito, Nobuyuki Oguri, Takaya Murashima, Toyoharu Kamibeppu, Takahiro Nagai, Hiroki Takamori, Toshio Kamimura, Shoichiro Mukai, Yuichiro Sato, Toshiyuki Kamoto
INTRODUCTION: Methotrexate induces lymphoproliferative disorders on rare occasions; however, its pathogenesis remains unknown. A clinical diagnosis based on imaging studies alone is often difficult. CASE PRESENTATION: A 57-year-old Japanese woman was referred to our department for the evaluation of multiple lung and hepatic nodules that developed during methotrexate treatment for rheumatoid arthritis. Since she had a history of nephrectomy for localized renal cell carcinoma, multiple lung and hepatic metastases were initially considered...
December 22, 2023: Journal of Medical Case Reports
#11
Tomoki Kato, Chisaki Mizumoto, Fuminori Inoue, Takuma Watanabe, Shigeki Yamanaka, Shizuko Fukuhara, Kazumasa Nakao
Methotrexate-related other iatrogenic immunodeficiency-associated lymphoproliferative disorder (MTX-OIIA-LPD) is prone to extranodal involvement but rarely involves the central nervous system (CNS). The present study reports a case of MTX-OIIA-LPD of the CNS discovered during medication-related osteonecrosis of the jaw (MRONJ) treatment in a 76-year-old woman with rheumatoid arthritis (RA). The chief complaint of the patient was bone exposure and pain in the right mandibular molar. The patient had been receiving MTX for RA and alendronate sodium hydrate for osteoporosis, followed by denosumab...
January 2024: Experimental and Therapeutic Medicine
#12
Ziyao Wang, Reiji Muto, Hiroaki Miyoshi, Mikiko Aoki, Noriko Uesugi, Hiroyuki Murayama, Kosuke Masutani, Makoto Hamasaki
This is the first autopsy case of Epstein-Barr virus-positive marginal zone lymphoma (EBV + MZL) with an other iatrogenic immunodeficiency-associated lymphoproliferative disorders (LPD) (methotrexate [MTX]-associated LPD) that deteriorated after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. This case had a unique immunophenotype. A 71-year-old female patient with rheumatoid arthritis receiving MTX presented with fatigue 1 week after the SARS-CoV-2 vaccination. She was hospitalized due to hepatorenal dysfunction and pancytopenia...
December 20, 2023: Pathology International
#13
JOURNAL ARTICLE
Misa Iimori, Kazuhiro Sonomura, Yuichi Ueyama, Yuki Oobayashi, Hiroya Adachi, Mayuka Nakayama
The patient was a 64-year-old man who had been receiving methotrexate (MTX) for rheumatoid arthritis for 8 years. Computed tomography (CT) obtained one month prior to admission revealed numerous enlarged lymph nodes. Lower leg edema appeared two weeks prior to admission. Severe proteinuria was confirmed, and the patient was admitted. A renal biopsy revealed minimal changes in glomeruli. CT on day 14 revealed shrinking lymph nodes, and the patient was diagnosed with Hodgkin lymphoma by a neck lymph node biopsy...
November 6, 2023: Internal Medicine
#14
JOURNAL ARTICLE
Jane Z Spadaro, Brittany Perzia, Sudhir Perincheri, Larissa Habib
An 80-year-old Caucasian female with a history of rheumatoid arthritis presented with a 6-month history of progressive right upper eyelid ptosis, edema, erythema, and pain. MRI demonstrated a superior orbital mass. An incisional biopsy was performed, and pathologic analysis revealed an atypical lymphoid infiltrate, co-expressing both B and T-cell markers, with a low proliferation rate. Flow cytometry and IgH rearrangement study did not demonstrate any B- or T-cell monoclonal proliferation. Based on these findings, she was diagnosed with an iatrogenic immunodeficiency-associated lymphoproliferative disorder...
January 2024: Ophthalmic Plastic and Reconstructive Surgery
#15
Chaninan Kositkuljorn, Suthinee Rutnin, Teerapong Rattananukrom, Teeraya Puavilai, Burana Khiankaew, Paisarn Boonsakan, Wimolsiri Iamsumang
Methotrexate-related lymphoproliferative disorders (MTX-LPDs) are immunodeficiency diseases following methotrexate (MTX) administration, mainly occurring in rheumatoid arthritis patients. Although uncommon, MTX-LPDs have been reported in some patients with psoriasis, dermatomyositis, and cutaneous T-cell lymphoma (CTCL) who received MTX. Granulomatous mycosis fungoides (GMF) is a rare subtype of cutaneous T-cell lymphoma, where MTX is one of the treatment options in recalcitrant cases. Herein, we report a case of a 72-year-old female patient with GMF who additionally developed cutaneous Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) during MTX treatment...
2023: Clinical, Cosmetic and Investigational Dermatology
#16
REVIEW
Alexander In, Brittany M Stopa, Joshua A Cuoco, Michael S Stump, Lisa S Apfel, Cara M Rogers
BACKGROUND: Methotrexate is an immunosuppressant commonly used to treat inflammatory conditions, such as rheumatoid arthritis. However, albeit exceedingly rare, it can have serious adverse effects within the central nervous system (CNS), such as methotrexate-associated lymphoproliferative disorder (MTX-LPD). Literature describing the natural history, treatment options, and clinical outcomes of patients with central nervous system MTX-LPD remains sparse. METHODS: We present a systematic literature review following PRISMA guidelines and a case illustration of CNS MTX-LPD...
August 11, 2023: World Neurosurgery
#17
JOURNAL ARTICLE
Marino Hiruma, Kumiko Tsuboi, Takahisa Hirose
No abstract text is available yet for this article.
August 1, 2023: Journal of Medical Ultrasonics
#18
Abinash Parajuli, Justine Chinnappan, Qazi Azher, Ghassan Bachuwa, Philip J Mcdonald
Lymphoproliferative disorder (LPD) is a severe adverse outcome of methotrexate (MTX) administration in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The immunosuppression caused is attributed to pathogenesis. Hence, discontinuation is the treatment. Reports on spontaneous tumor lysis with cessation of MTX are rare. We report a case of a female in her 50s with methotrexate-associated lymphoproliferative disease (MTX-LPD) following treatment for rheumatoid arthritis. Methotrexate was discontinued immediately...
June 2023: Curēus
#19
REVIEW
Philip S Macklin, Rachel Fisher, Christopher Stonard, Rubeta N Matin, Eleni Ieremia
Immunodeficiency-associated lymphoproliferative disorders (IA-LPDs) constitute a diverse range of conditions including posttransplant lymphoproliferative disorders, other iatrogenic IA-LPDs, and lymphoproliferative disorders associated with an underlying primary immune disorder or HIV infection. IA-LPDs are clinically and pathologically heterogeneous, and there is a lack of standardization of diagnostic terminology. They can represent a potential serious diagnostic pitfall because the histological features of clinically indolent proliferations may mimic those of high-grade lymphoma...
August 1, 2023: American Journal of Dermatopathology
#20
Takaki Kitamura, Tomonori Shigemura, Yohei Yamamoto, Yasuaki Murata
The incidence of lymphoproliferative disorders associated with methotrexate is rising in patients with rheumatoid arthritis. These disorders typically exhibit spontaneous tumor regression upon discontinuation of methotrexate therapy. Spinal lesions associated with these diseases are extremely rare. We present a case of systemic lupus erythematosus in which the patient developed lumbar spine lymphoproliferative disorders secondary to methotrexate therapy, which failed to regress despite discontinuation of the drug, ultimately leading to pathological fracture necessitating posterior spinal fixation...
June 2023: Curēus
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
